Operator
Ladies and gentlemen, thank you for standing by. Welcome to Pulmonx’ Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would like now to turn the call over to Webb Campbell, Investor Relations. Please go ahead.
Webb Campbell
Gilmartin Group LLC
Good afternoon, and thank you for joining today’s call. Joining me from Pulmonx are Glen French, President and Chief Executive Officer; and Derrick Sung, Chief Operating Officer and Chief Financial Officer. Earlier today, Pulmonx issued a press release announcing its financial results for the quarter-ended June 30, 2026. A copy of the press release is available on the Pulmonx website.
Before we begin, I’d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.
All forward-looking statements, including, without limitations, those related to our operating trends, commercial strategies and future financial performance including long-term outlook and full year 2026 guidance, the timing and results of clinical trials, physician engagement, expense management, market opportunity, guidance for revenue, gross margin, operating expense, cash usage, commercial expansion and product demand, adoption and pipeline development are based upon our current estimates and various
